274 related articles for article (PubMed ID: 28740920)
1. Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer.
Chen VE; Gillespie EF; Zakeri K; Murphy JD; Yashar CM; Lu S; Einck JP
Adv Radiat Oncol; 2017; 2(2):105-109. PubMed ID: 28740920
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
[TBL] [Abstract][Full Text] [Related]
3. [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy].
Rong QL; Wang SL; Tang Y; Jin J; Song YW; Wang WH; Liu YP; Fang H; Ren H; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):445-452. PubMed ID: 28635235
[No Abstract] [Full Text] [Related]
4. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy.
Buchholz TA; Katz A; Strom EA; McNeese MD; Perkins GH; Hortobagyi GN; Thames HD; Kuerer HM; Singletary SE; Sahin AA; Hunt KK; Buzdar AU; Valero V; Sneige N; Tucker SL
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):880-8. PubMed ID: 12095553
[TBL] [Abstract][Full Text] [Related]
5. Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy.
Krug D; Vladimirova V; Untch M; Kühn T; Schneeweiss A; Denkert C; Ataseven B; Solbach C; Gerber B; Tesch H; Golatta M; Seiler S; Heil J; Nekljudova V; Holtschmidt J; Loibl S
Breast; 2024 Apr; 74():103701. PubMed ID: 38422624
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
7. Locoregional and Distant Outcomes in Women With cT1-3N1 Breast Cancer Treated With Neoadjuvant Chemotherapy With or Without Adjuvant Radiotherapy.
Kozak MM; von Eyben R; Gutkin PM; Vemuri M; Jacobson CE; Karl JJ; Walck E; Marquez C; Horst KC
Clin Breast Cancer; 2021 Aug; 21(4):373-382. PubMed ID: 33766533
[TBL] [Abstract][Full Text] [Related]
8. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
Kozak MM; Jacobson CE; von Eyben R; Pollom EL; Telli M; Horst KC
J Natl Compr Canc Netw; 2018 Jul; 16(7):845-850. PubMed ID: 30006427
[No Abstract] [Full Text] [Related]
9. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation.
Wright JL; Takita C; Reis IM; Zhao W; Saigal K; Wolfson A; Markoe A; Moller M; Hurley J
Cancer; 2013 Jan; 119(1):16-25. PubMed ID: 22736498
[TBL] [Abstract][Full Text] [Related]
10. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
Garg AK; Strom EA; McNeese MD; Buzdar AU; Hortobagyi GN; Kuerer HM; Perkins GH; Singletary SE; Hunt KK; Sahin A; Schechter N; Valero V; Tucker SL; Buchholz TA
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):138-45. PubMed ID: 15093909
[TBL] [Abstract][Full Text] [Related]
11. Impact of Postmastectomy Radiation Therapy on Breast Cancer Patients According to Pathologic Nodal Status after Modern Neoadjuvant Chemotherapy.
Kim D; Kim JH; Kim IA; Chang JH; Shin KH
Cancer Res Treat; 2023 Apr; 55(2):592-602. PubMed ID: 36228653
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Locoregional Recurrence After Failure to Achieve Pathologic Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Gabani P; Merfeld E; Srivastava AJ; Weiner AA; Ochoa LL; Mullen D; Thomas MA; Margenthaler JA; Cyr AE; Peterson LL; Naughton MJ; Ma C; Zoberi I
J Natl Compr Canc Netw; 2019 Apr; 17(4):348-356. PubMed ID: 30959467
[TBL] [Abstract][Full Text] [Related]
13. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
14. Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy.
Zhang C; Wang S; Israel HP; Yan SX; Horowitz DP; Crockford S; Gidea-Addeo D; Clifford Chao KS; Kalinsky K; Connolly EP
Springerplus; 2015; 4():386. PubMed ID: 26240784
[TBL] [Abstract][Full Text] [Related]
15. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
16. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
17. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
[TBL] [Abstract][Full Text] [Related]
18. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
[TBL] [Abstract][Full Text] [Related]
19. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05).
Shim SJ; Park W; Huh SJ; Choi DH; Shin KH; Lee NK; Suh CO; Keum KC; Kim YB; Ahn SD; Kim SS; Ha SW; Chie EK; Kim K; Shin HS; Kim JH; Lee HS
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):65-72. PubMed ID: 24161425
[TBL] [Abstract][Full Text] [Related]
20. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation.
Buchholz TA; Tucker SL; Masullo L; Kuerer HM; Erwin J; Salas J; Frye D; Strom EA; McNeese MD; Perkins G; Katz A; Singletary SE; Hunt KK; Buzdar AU; Hortobagyi GN
J Clin Oncol; 2002 Jan; 20(1):17-23. PubMed ID: 11773149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
